Checkpoint Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
Checkpoint Therapeutics has a total shareholder equity of $-13.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $5.4M and $18.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$4.93m |
| Equity | -US$13.05m |
| Total liabilities | US$18.43m |
| Total assets | US$5.38m |
Recent financial health updates
We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate
Sep 20
Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?
May 18Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth
Feb 15Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans
Oct 30Recent updates
We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate
Sep 20Checkpoint: Strong Data, But Comes With Risks
Sep 08Checkpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01M
Aug 12Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?
May 18Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions
Apr 18Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth
Feb 15Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results
Jan 28Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout
Nov 26Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans
Oct 30We're Not Very Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate
Jul 17Checkpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab Data
Jul 14Checkpoint Therapeutics (CKPT) Investor Presentation - Slideshow
Jun 21Checkpoint surges 24% on B. Riley buy initiation, 567% upside potential
Jun 09It's Unlikely That Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) CEO Will See A Huge Pay Rise This Year
Jun 02The Checkpoint Therapeutics (NASDAQ:CKPT) Share Price Is Up 141% And Shareholders Are Boasting About It
Mar 11Have Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Insiders Been Selling Their Stock?
Feb 06
Do Institutions Own Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Shares?
Jan 27Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth
Dec 23What We Learned About Checkpoint Therapeutics' (NASDAQ:CKPT) CEO Pay
Nov 27Checkpoint Therapeutics +10% after expanding cosibelimab manufacturing deal with Samsung Biologics
Nov 02Financial Position Analysis
Short Term Liabilities: CKPT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: CKPT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: CKPT is debt free.
Reducing Debt: CKPT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CKPT has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: CKPT is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.